Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povorcitinib QT/QTc study in healthy participants
NCT06441318Phase 1Completed
- Sponsor
- Incyte
- Start
- Jul 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of povorcitinib in hidradenitis suppurativa (HS), Vitiligo and prurigo nodularis (PN) (4 arms), sponsored by Incyte. Primary endpoints: Change from Baseline in QT interval corrected using Fridericia's formula, Change from Baseline in heart rate and 2 more. Started Jul 2024; status: completed.
02
Drugs
povorcitinib
03
Conditions
hidradenitis suppurativa (HS)Vitiligoprurigo nodularis (PN)
Beyond the preview
Go deeper on NCT06441318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06441318.